PRIMARY STUDY

Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial

Key Findings:  Among patients with diabetes who were given gemigliptin, compared to placebo there were significant improvements in biomarkers of vascular and renal function, including improved levels of liver fatty acid-binding protein (L-FABP)/Cr.